Summary
This narrative review synthesises evidence on how catechins—polyphenolic compounds from green tea (Camellia sinensis)—exert neuroprotective effects in neurodegenerative diseases. The authors examine catechins' biological mechanisms including oxidative stress reduction, anti-inflammatory signalling, inhibition of pathological protein accumulation (tau, amyloid-beta, alpha-synuclein), and dopamine modulation, with application to Alzheimer's disease, Parkinson's disease, multiple sclerosis, and cognitive impairment. The review highlights that whilst no definitive cure exists for these disorders, catechins represent a potentially preventative or adjunctive therapeutic approach supported by both mechanistic and human epidemiological evidence.
UK applicability
Green tea is widely available and consumed in the United Kingdom; catechin bioavailability and cognitive benefit may vary with individual genetic and gut microbiota factors. Clinical translation would require rigorous randomised controlled trials in UK populations to establish efficacy, dosage, and safety relative to existing treatments for neurodegenerative disease.
Key measures
Catechin bioactivity assessed via antioxidant capacity, free radical scavenging, metal chelation, tau phosphorylation inhibition, amyloid-beta aggregation, alpha-synuclein levels, and dopamine levels; human cognitive and disease outcomes from interventional and observational studies
Outcomes reported
The review examined catechins' neuroprotective mechanisms across multiple neurodegenerative diseases including Alzheimer's, Parkinson's, and multiple sclerosis, and their effects on cognitive deficits. Evidence from human interventional and observational studies was synthesised alongside mechanistic data on antioxidant, anti-inflammatory, and protein-modulating pathways.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.